| Roche Pharma (Schweiz) AG - Madopar 250, Tabletten | | 43593 | | 01 | | Madopar 250 | | Tabletten | | N04BA02 | | Levodopa and Decarboxylase Inhibitor | | 27.01.1981 | | |
| | Composition | | levodopum 200.00 mg, benserazidum 50.00 mg ut benserazidi hydrochloridum, mannitolum, calcii hydrogenophosphas, cellulosum microcristallinum, amylum pregelificatum, crospovidonum, ethylcellulosum, E 172 (rubrum), silica colloidalis anhydrica, natrii docusas corresp. natrium 0.01 mg, magnesii stearas, pro compresso. | | Packungsbestandteile | | Comprimés | | | | | Active Agent | Dose |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | BAG: Active Agent | Dose |
|---|
| Benserazide | 50 mg | | Levodopa | 200 mg |
| | | | Inactive agents | | additional_information |
|---|
| | | | | | | | | Calcium Hydrogenophosphate | | | | | | | | | | | | | | color. | | | | | | | | | | Mannitol | | | | Natrii Docusas | | | | | | | | Silica Colloidalis Anhydrica | | |
| |
| | Teilbarkeit | | | Ja (Bruchrille) | | | | Nein | | | | Nein | | | | -- | | | | Teilbar entlang der Bruchkerbe, aber nicht weiter zerkleinern. Vorschlag: Madopar LIQ (= wasserlösliche Tabletten) verwenden. [2] | | | | | [2] Firmeninformation |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 013 | 30 Comprimé(s) | 8.76 | 18.55 | B | SL | No | | 021 | 100 Comprimé(s) | 26.64 | 44.80 | B | SL | No |
|
|
